Merck's Keytruda, Amgen's treatment stand out at oncology meeting

Genocea Biosciences

03/06/2019 16:07

(Updates)
    ** Amgen Inc  AMGN.O  shares up 5% after presenting
promising early-stage data from an experimental cancer therapy;
biggest boost to Nasdaq Biotech index  .NBI , which is up 1.5% 
    ** Jefferies calls AMGN's AMG 510 targeting specific
mutation a potential blockbuster; shares of Mirati Therapeutics
Inc  MRTX.O , which is also targeting the same mutation, jump
more than 35%  urn:newsml:reuters.com:*:nL4N23A3C2
    ** Cancer drug developers are presenting new data at
American Society of Clinical Oncology (ASCO) annual meeting in
Chicago
    ** Merck & Co  MRK.N  also presents data on its blockbuster
cancer drug Keytruda; Credit Suisse says the "impressive
results" in non-small cell lung cancer boost drug's long-term
prospects 
    ** Nektar Therapeutics  NKTR.O  shares up ~12% as analysts
talk up co's cancer treatment bempegaldesleukin's data
 urn:newsml:reuters.com:*:nL4N23A35K
    ** Genocea Biosciences Inc  GNCA.O  shares up ~54% after co
announces promising data from its ongoing trial of GEN-009, its
lead cancer treatment vaccine, at ASCO  urn:newsml:reuters.com:*:nL4N23A2X7
    ** RBC Capital Markets says Celgene's  CELG.O  cancer
treatment CC-220 continues to show promise as treatment for
refractory multiple myeloma; says data suggests potential role
for CC-220 to be used as a part of future combo treatments 
    ** Guggenheim says majority of updates given at ASCO were
"incremental", but highlights data from Blueprint Medicines
 BPMC.O , Immunomedics  IMMU.O , BeiGene  6160.HK , Clovis
 CLVS.O , ImmunoGen  IMGN.O , bluebird bio  BLUE.O  among others

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Reuters Messaging:
Aakash.B.thomsonreuters.com@reuters.net))